Resolution Therapeutics Will Present Liver Trial Data
New findings on macrophage cell therapy in liver disease will arrive at a major Denver conference this November.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe medical research is currently improving treatment options for patients with chronic diseases?
Resolution Therapeutics will present interim data from the Phase I/II EMERALD study at the American Association for the Study of Liver Diseases conference on November 8, 2026. This research-stage trial evaluates the safety and efficacy of RTX001 in patients who have recovered from recent hepatic decompensation.
Why it matters
The trial aims to address the critical need for new treatments for end-stage liver disease, a condition that currently affects 500,000 Americans. Addressing the inflammation and fibrosis underlying this disease is a key focus for regenerative medicine as the patient population is projected to grow to 600,000 by 2040.
The EMERALD trial assesses the safety and tolerability of RTX001, a macrophage-based therapy. It targets patients with a high mortality rate, where 37% of individuals die within two years of decompensation while only 5% receive a transplant.
The players
Resolution Therapeutics
An Edinburgh and London-based biotechnology company developing macrophage cell therapies to treat chronic inflammatory diseases.
Dr. Lara Campana
A researcher focused on the development of regenerative macrophage therapies for liver cirrhosis.
The details
Resolution Therapeutics uses a proprietary platform to engineer macrophages—specialized immune cells that engulf cellular debris and pathogens—to possess pro-regenerative properties. By injecting these modified cells, the company attempts to modulate the liver microenvironment to suppress fibrosis, the formation of excess scar tissue, and inflammation. This approach seeks to restart the body's natural tissue repair processes in patients following a recent episode of hepatic decompensation, a sudden worsening of liver function.
Timeline
November 5-9, 2026: The Liver Meeting takes place in Denver, Colorado.
November 7, 2026, 08:30 MST: Dr. Lara Campana will present preclinical data on intravenous Regenerative Macrophage Therapy.
November 8, 2026, 13:00 MST: Resolution Therapeutics will present interim data from the EMERALD trial.
2040: Projected timeframe for the U.S. end-stage liver disease population to reach 600,000.
The Tech Race
This presentation at the American Association for the Study of Liver Diseases conference highlights the intensifying push to develop cell-based regenerative therapies for chronic liver conditions. It sits within a competitive landscape of emerging biotechnologies attempting to move beyond traditional transplant standards.
This development is currently in the research stage and has not reached clinical availability for patients. Residents of Denver can observe the impact of this trial as part of the broader discussion on managing liver disease at the upcoming medical conference.
The takeaway
The EMERALD trial interim data will provide the first clinical-stage look at whether programmed macrophages can meaningfully change survival outcomes in liver disease. Observers should track the presentation scheduled for November 8, 2026, for specific safety and tolerability metrics.
Further reading
For more on emerging developments in cell therapy, see Biotech.
Live Poll
Do you believe medical research is currently improving treatment options for patients with chronic diseases?
